Early response to therapy and outcome in childhood acute lymphoblastic leukemia: A review

Cancer

Volumn 80, Issue 9, 1997, Pages 1717-1726

  Gaynon, Paul S ^a   Desai, Anish A ^a   Bostrom, Bruce C ^b   Hutchinson, Raymond J ^c   Lange, Beverly J ^d   Nachman, James B ^e   Reaman, Gregory H ^f   Sather, Harland N ^g   Steinherz, Peter G ^h   Trigg, Michael E ⁱ   Tubergen, David G ^j   Uckun, Fatih M ^k  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

Childhood acute lymphoblastic leukemia; Prognostic factors; Response

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; DRUG RESPONSE; HUMAN; INFANT; INTRATHECAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW EXAMINATION; CHILD; CLINICAL TRIALS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030720796     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B     Document Type: Review

References (49)

1. King SC, Reiman RJ, Prosnitz LR. Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease. J Clin Oncol 1994;12:306-11.
2. Kaplan WD, Jochelson MS, Herman TS, Nadler LM, Stomper PC, Takvorian T, et al. Gallium-67 imaging: a predictor of residual tumor viability clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990;8:1966-70.
3. Haq R, Sawka CA, Franssen E, Berinstein NL. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. J Clin Oncol 1994;12:1074-84.
4. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423-31.
5. Picci P, Rougraff BT, Bacci G, Neff JR, Sangiorgi L, Cazzola A, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol 1993;11:1763-9.
6. Chauvet B, Félix-Faure C, Lupsascka N, Fijuth J, Brewer Y, Davin J-L, et al. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy. J Clin Oncol 1994;2:1402-7.
7. Keating MJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, Spitzer G, et al. Factors related to length of complete remission in adult acute leukemia. Cancer 1980;45:2017-29.
8. Moore DF, Estey E. Prognostic value of the day 14 bone marrow examination in newly diagnosed AML [abstract 1820]. Blood 1991;78:457a.
9. Jacquillat C, Weil M, Gemon M-F, Auclerc G, Loisel J-P, Delobel J, et al. Combination therapy in 130 patients with acute lymphoblastic leukemia (Protcol 06 LA 66-Paris). Cancer Res 1973;33:3278-84.
10. Miller DR, Leikin S, Albo V, Vitale L, Sather H, Coccia P, et al. Use of prognostic factors in improving the design and efficiency of clinical trials for childhood leukemia: Children's Cancer Study Group report. Cancer Treat Rep 1980;64:381-92.
11. Miller DR, Leikin S, Albo V, Sather H, Karon M, Hammond D. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141: a report from Children's Cancer Study Group. Cancer 1983;51:1041-9.
12. Hammond D, Sather H, Nesbit M, Miller D, Coccia P, Bleyer A, et al. Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol 1986;14:124-34.
13. Miller DR, Coccia PF, Bleyer WA, Lukens JN, Siegel SE, Sather HN, et al. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group. J Clin Oncol 1989;7:1807-15.
14. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia: the importance of early marrow response. Report from the Children's Cancer Group. J Clin Oncol 1996;14:389-98.
15. Hutchinson R, Bertolone S, Cooper H, Roskos R, Wells L, Heerema N, et al. Early marrow response predicts outcome for patients with low-risk ALL: results of CCG-1881 [abstract 1051]. Proc Am Soc Clin Oncol 1994;13:319.
16. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of the UK Medical Research Council trial UKALL X. Lancet 1995;345:143-8.
17. Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman P, Miller DR, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990;18:273-9.
18. Lange B, Sather H, Weetman R, Cherlow J, McGuire-Cullen P, Arthur D, et al. Predictive value of early response in intermediate risk acute lymphoblastic leukemia in children, Children's Cancer Group (CCG) 1891 [abstract]. Blood 1995; 86:767a.
19. Rautonen I, Hovi L, Siimes MA. Slow disappearance of peripheral blast cells: an independent risk factor indicating poor prognosis in children with acute lymphoblastic leukemia. Blood 1988;71:989-91.
20. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, et al. Die corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83). Klin Padiatr 1986;199:151-60.
21. Riehm H, Feickert H-J, Schrappe M, Henze G, Schellong G. Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. Hamatol Bluttransfus 1987;30:139-46.
22. Aricò M, Basso G, Mandelli F, Rizzari C, Colella R, Barisone E, et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. Cancer 1995;75:1684-93.
23. Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995;86:1292-5.
24. Reiter A, Schrappe M, Ludwig WD, Hiddeman W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33.
25. Schrappe M, Reiter A, Sauter S, Ludwig WD, Wörmann B, Harbott J, et al. Konzeption und Zwischenergebnis der Therapiestudie ALL-BFM 90 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: die Bedeutung des initialen Therapieansprechens in Blut und Knochenmark. Klin Padiatr 1994;206:208-21.
26. Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Children's Cancer Group phase III trial. J Clin Oncol 1993;11:527-37.
27. Duque-Hammershaimb L, Wollner N, Miller DR. LSA2-L2 protocol treatment of stage IV non-Hodgkin's lymphoma in children with partial and extensive bone marrow involvement. Cancer 1983;52:39-43.
28. Steinherz PG, Gaynon P, Miller DR, Reaman G, Bleyer A, Finklestein J, et al. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen: a new intensive therapy protocol: a report from the Children's Cancer Study Group. J Clin Oncol 1986;4:744-52.
29. Nachman J, Lukens J, Gaynon P, Magenis E, Wolff L, Sather H, et al. Predictors of slow early response (SER) to BFM induction therapy in children and young adults with acute lymphoblastic leukemia (ALL): a report from Children's Cancer Group (CCG) [abstract 1018]. Blood 1992;80:257a.
30. Thyss A, Munzer C, Mechinaud-Lacroix F, Boutard P, Suicui S, Tokaji E, et al. Intrathecal methotrexate (I.T. MTX) is an important factor of the response to the so-called "corticoid prephase" of the BFM protocol for ALL in the EORTC 58881 trial [abstract 31]. Med Pediatr Oncol 1993;21:539.
31. Pession A, Rondelli R, Vecchi V, Conter V, Aricò M, Covezzoli A, et al. Preinduction therapy response in childhood ALL protocols ('87-'88) of the Italian Association for Pediatric Hematology and Oncology (AIEOP) [abstract P1]. Med Pediatr Oncol 1993;21:555.
32. Schrappe M, Reiter A, Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol 1996;14:2403-5.
33. Hagenbeek A, Martens ACM. Minimal residual disease in acute leukemia: lessons learned from animal models. Hamatol Bluttransfus 1990;33:31-5.
34. Wasserman R, Galili N, Ito Y, Silber JH, Reichard BA, Shane S, et al. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992;10:1879-88.
35. Brisco MJ, Condon J, Hughes E, Neoh S-H, Syke PJ, Seshadri R, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994;343:196-200.
36. Uckun FM, Kersey JH, Haake R, Weisdorf D, Nesbit ME, Ramsay NKC. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. N Engl J Med 1993;329:1296-1301.
37. Campana D, Pui CH. Minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995;85:1416-34.
38. Price CGA, Meerabux J, Murtagh S, Cotter FE, Rohatiner AZS, Young BD, et al. The significance of circulating cells carrying t(14; 18) in long remission from follicular lymphoma. J Clin Oncol 1991;9:1527-32.
39. Limpens J, Stad R, Vos C, de Vlaam C, de Jong D, van Ommen G-JB, et al. Lymphoma-associated translocation t(14; 18) in blood B cells of normal individuals. Blood 1995;85:2528-36.
40. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995;86:3118-22.
41. Pieters R, Kaspers GJL, Klumper E, Veerman AJP. Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: the state of the art. Med Pediatr Oncol 1994;22:299-308.
42. Pieters R, Kaspers GJL, van Wering ER, van der Does-van den Berg A, Veerman AJP. Prospective study of the in vitro prednisolone resistance in childhood acute lymphoblastic leukemia: a new risk factor in BFM-oriented treatment [abstract 762]. Blood 1993;82:194a.
43. Hongo T, Sakakura Y, Yajima S, Inoue N, Saurai M. Induction failure and early relapse of childhood acute lymphoblastic leukemia can be predicted by in vitro drug sensitivity test [abstract O-71]. Med Pediatr Oncol 1996;27:229.
44. Nachman J, Sather H, Lukens J, Gaynon P, Wolff L, Arthur D, et al. Intrathecal methotrexate is sufficient central nervous system prophylaxis for high risk patients with acute lymphoblastic leukemia (ALL) showing a rapid early response (RER) to BFM induction chemotherapy. Blood 1995;86:265a.
45. Nachman J, Sather H, Lukens J, Gaynon P, Wolff L, Arthur D, et al. Children's Cancer Group (CCG) Study 1882. Augmented BFM (A-BFM) for treatment of children and young adults with high risk acute lymphoblastic leukemia (ALL) showing slow early response (SER) [abstract 1039]. Proc Am Soc Clin Oncol 1995;14:344.
46. Butturini A, Bortin MM, Rivera GK, Gale RP. Which treatment for childhood acute lymphoblastic leukaemia in second remission? Lancet 1987;i:429-32.
47. Barrett AJ, Horowitz MM, Pollock BH, Zhang M-J, Bortin MM, Buchanan GR, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994;331:1253-8.
48. Cline MJ. The molecular basis of leukemia. N Engl J Med 1994;330:328-36.
49. Rainier S, Feinberg AP. Genomic imprinting, DNA methylation, and cancer. J Natl Cancer Inst 1994;86:753-9.